A Two Part, Non-randomised, Open Label Study Designed to Assess the Pharmacokinetic Profile of Modified Release Prototype Coated Tablet Formulations of GSK2982772 Relative to an Immediate Release Reference Tablet Formulation at a Fixed Strength (Part A) and the Pharmacokinetic Profile of Alternative Tablet Strengths of the Selected Modified Release Prototype Coated Tablet Formulation (Part B, Optional) in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs GSK 2982772 (Primary) ; GSK 2982772
- Indications Autoimmune disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 17 Jun 2019 Status changed from recruiting to completed.
- 14 Mar 2019 Planned End Date changed from 24 Apr 2019 to 19 Apr 2019.
- 14 Mar 2019 Planned primary completion date changed from 29 Mar 2019 to 19 Apr 2019.